Literature DB >> 29407948

Rational design, chemical synthesis and biological evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists.

Sara Guariento1, Michele Tonelli2, Stefano Espinoza3, Andrey S Gerasimov4, Raul R Gainetdinov5, Elena Cichero6.   

Abstract

The design of novel chemical classes acting towards several G-protein-coupled receptors (GPCRs) represents a leading strategy in drug discovery, aimed at deriving effective and safe candidates for further assessment. During the last years, TAAR1 arose as a promising druggable target in medicinal chemistry, being of interest in the treatment of several pathologies, such as neuropsychiatric disorders, type 2 diabetes and obesity. Nevertheless, the limited number of known potent and selective ligands and the species-specificity responsiveness exhibited by those derivatives nowadays available make the discovery of novel compounds a challenging task. Herein, we discuss the development of two quantitative-structure activity relationship (QSAR) models around the agonism ability experienced by different chemo-types toward murine and human TAAR1 (m/hTAAR1) with the aim at deciphering some clues involved in their species-specificity responsiveness. Qualitatively, these information were evaluated guiding for the synthesis of novel ligands, which proved to feature selective agonism ability with respect to the mTAAR1 and hTAAR1 orthologues.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Agonists; Biguanide; Docking; QSAR; TAAR1; Thyronamines

Mesh:

Substances:

Year:  2018        PMID: 29407948     DOI: 10.1016/j.ejmech.2018.01.059

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  New 2-[(4-Amino-6-N-substituted-1,3,5-triazin-2-yl)methylthio]-N-(imidazolidin-2-ylidene)-4-chloro-5-methylbenzenesulfonamide Derivatives, Design, Synthesis and Anticancer Evaluation.

Authors:  Łukasz Tomorowicz; Beata Żołnowska; Krzysztof Szafrański; Jarosław Chojnacki; Ryszard Konopiński; Ewa A Grzybowska; Jarosław Sławiński; Anna Kawiak
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

2.  Molecular Docking Studies of a Cyclic Octapeptide-Cyclosaplin from Sandalwood.

Authors:  Abheepsa Mishra; Satyahari Dey
Journal:  Biomolecules       Date:  2019-11-15

3.  Discovery and In Vivo Efficacy of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 4-(2-Aminoethyl)-N-(3,5-dimethylphenyl)piperidine-1-carboxamide Hydrochloride (AP163) for the Treatment of Psychotic Disorders.

Authors:  Mikhail Krasavin; Anatoly A Peshkov; Alexey Lukin; Kristina Komarova; Lyubov Vinogradova; Daria Smirnova; Evgeny V Kanov; Savelii R Kuvarzin; Ramilya Z Murtazina; Evgeniya V Efimova; Maxim Gureev; Kirill Onokhin; Konstantin Zakharov; Raul R Gainetdinov
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

4.  Synthesis, Antitumor Evaluation, Molecular Modeling and Quantitative Structure-Activity Relationship (QSAR) of Novel 2-[(4-Amino-6-N-substituted-1,3,5-triazin-2-yl)methylthio]-4-chloro-5-methyl-N-(1H-benzo[d]imidazol-2(3H)-ylidene)Benzenesulfonamides.

Authors:  Łukasz Tomorowicz; Jarosław Sławiński; Beata Żołnowska; Krzysztof Szafrański; Anna Kawiak
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

5.  Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.

Authors:  Michele L R Heffernan; Lee W Herman; Scott Brown; Philip G Jones; Liming Shao; Michael C Hewitt; John E Campbell; Nina Dedic; Seth C Hopkins; Kenneth S Koblan; Linghong Xie
Journal:  ACS Med Chem Lett       Date:  2021-12-06       Impact factor: 4.345

6.  Probing Allosteric Hsp70 Inhibitors by Molecular Modelling Studies to Expedite the Development of Novel Combined F508del CFTR Modulators.

Authors:  Roberto Sabbadini; Emanuela Pesce; Alice Parodi; Eleonora Mustorgi; Santina Bruzzone; Nicoletta Pedemonte; Monica Casale; Enrico Millo; Elena Cichero
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.